ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO044

Cannabis Use and Its Association with Incidence of AKI in Advanced CKD Patients Transitioning to ESRD

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Potukuchi, Praveen Kumar, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Sumida, Keiichi, Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, kanagawa, Japan
  • Molnar, Miklos Zsolt, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Gaipov, Abduzhappar, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Park, Frank, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Kaplan, Cameron M., University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Moradi, Hamid, University of California Irvine, School of Medicine, Orange, California, United States
  • Thomas, Fridtjof, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Gatwood, Justin, University of Tennessee Health Science Center, Memphis, Tennessee, United States
  • Streja, Elani, Harold Simmons Center for Kidney Disease Research and Epidemiology, Orange, California, United States
  • Kalantar-Zadeh, Kamyar, University of California Irvine, School of Medicine, Orange, California, United States
  • Kovesdy, Csaba P., University of Tennessee Health Science Center, Memphis, Tennessee, United States
Background

Cannabinoid receptors are expressed in the kidneys and their stimulation may have both harmful and beneficial effects. Synthetic cannabinoid use is associated with acute kidney injury (AKI) in case reports, but the effects of cannabis use on the incidence of AKI in patients with advanced CKD is unknown.

Methods

We examined 2,416 US veterans who transitioned to dialysis during 2007-2014 and had undergone urine toxicology tests up to one year prior to dialysis, and had serial serum creatinine levels measured within 7 days after the test. We compared patients whose toxicology tests were positive for cannabis alone (primary exposure group, PEG, N=76) with those whose tests were negative (negative control group, NCG, N=1,138). AKI was defined according to KDIGO creatinine–based criteria. We examined the association of cannabis use with AKI using logistic regression adjusted for sociodemographics, comorbidities, medications, and vital signs.

Results

The mean (SD) age of the cohort was 60.6 (9.3) years; 97% were male, 46.7 % were African American and 76.4% were diabetic. AKI occurred in 58.6% of the cohort. Cannabis use was not associated with the odds of AKI in crude or in multivariable adjusted models (multivariable adjusted odds ratios (and 95%CI) in PEG vs. NCG: 0.75 (0.45-1.24); Figure 1).

Conclusion

Cannabis use in advanced CKD patients is not associated with the incidence of AKI.

Funding

  • NIDDK Support